The Latest Breaking News from Joaquin Duato

L'Oréal increasingly is capable of personalization, or as CEO Nicolas Hieronimus puts it, "beauty that's tailor-made" for each consumer.

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

With the Fed anticipating higher interest rate hikes than previously expected, the stock market is expected to remain volatile in the upcoming months. Given its strong balance sheet, brand recognition, and solid dividend payouts, it could be safe to invest in Johnson & Johnson (JNJ). Read more….

Johnson & Johnson (JNJ) continued its business momentum in the third quarter of fiscal 2022, driven by steady demand for its products and innovative, advancing portfolio and pipeline. Moreover, the company has a record of raising its dividend for 60 consecutive years. Amid the current uncertain market conditions, this fundamentally…

Leading healthcare company Johnson & Johnson (JNJ) has been able to navigate the volatile market conditions due to the defensive nature of its business and solid fundamentals. Moreover, the company has an impressive history of increasing its dividends. Given JNJ’s robust financials, high profitability, and consistent dividend payouts, we think…

"The addition of Abiomed is an important step in our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech," said CEO Joaquin Duato.

“Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said CEO Joaquin Duato.

"We have the ability to invest in innovation, grow our dividend, execute strategic acquisitions, and take this action to deliver shareholder returns," said CEO Joaquin Duato.

"Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our company’s market leadership in the midst of macroeconomic challenges,” said CEO Joaquin Duato.